Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneGene 2: PF-06838435 gene transfer in adult males with moderately severe to severe hemophilia B
KCT0008736Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on KCT0008736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008736.